These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20354916)

  • 1. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery.
    Liu Y; Liu J; Zhang X; Zhang R; Huang Y; Wu C
    AAPS PharmSciTech; 2010 Jun; 11(2):610-20. PubMed ID: 20354916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
    Geethalakshmi A; Karki R; Jha SK; Venkatesh DP; Nikunj B
    Curr Drug Deliv; 2012 Mar; 9(2):197-204. PubMed ID: 22283647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.
    Rupenthal ID; Green CR; Alany RG
    Int J Pharm; 2011 Jun; 411(1-2):78-85. PubMed ID: 21453763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ gelling of alginate/pluronic solutions for ophthalmic delivery of pilocarpine.
    Lin HR; Sung KC; Vong WJ
    Biomacromolecules; 2004; 5(6):2358-65. PubMed ID: 15530052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time.
    Destruel PL; Zeng N; Seguin J; Douat S; Rosa F; Brignole-Baudouin F; Dufaÿ S; Dufaÿ-Wojcicki A; Maury M; Mignet N; Boudy V
    Int J Pharm; 2020 Jan; 574():118734. PubMed ID: 31705970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheological evaluation of Gelrite in situ gels for ophthalmic use.
    Carlfors J; Edsman K; Petersson R; Jörnving K
    Eur J Pharm Sci; 1998 Apr; 6(2):113-9. PubMed ID: 9795027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops.
    Sultana Y; Aqil M; Ali A
    Drug Deliv; 2006; 13(3):215-9. PubMed ID: 16556574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin.
    Liu Z; Li J; Nie S; Liu H; Ding P; Pan W
    Int J Pharm; 2006 Jun; 315(1-2):12-7. PubMed ID: 16616442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery.
    Noreen S; Ghumman SA; Batool F; Ijaz B; Basharat M; Noureen S; Kausar T; Iqbal S
    Int J Biol Macromol; 2020 Jun; 152():1056-1067. PubMed ID: 31751751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system.
    Sayed EG; Hussein AK; Khaled KA; Ahmed OA
    Drug Des Devel Ther; 2015; 9():1427-35. PubMed ID: 25792803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation.
    Bhalerao H; Koteshwara KB; Chandran S
    AAPS PharmSciTech; 2019 Aug; 20(7):272. PubMed ID: 31372767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model.
    Sultana Y; Aqil M; Ali A; Zafar S
    Pharm Dev Technol; 2006; 11(3):313-9. PubMed ID: 16895842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbopol/pluronic phase change solutions for ophthalmic drug delivery.
    Lin HR; Sung KC
    J Control Release; 2000 Dec; 69(3):379-88. PubMed ID: 11102678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride.
    Balasubramaniam J; Pandit JK
    Drug Deliv; 2003; 10(3):185-91. PubMed ID: 12944139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation.
    Bhalerao H; Koteshwara KB; Chandran S
    AAPS PharmSciTech; 2020 Jan; 21(2):69. PubMed ID: 31950311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.
    Rupenthal ID; Green CR; Alany RG
    Int J Pharm; 2011 Jun; 411(1-2):69-77. PubMed ID: 21453762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and In Vitro Release Kinetics of Mucoadhesive Blend Gels Containing Matrine for Buccal Administration.
    Chen X; Yan J; Yu S; Wang P
    AAPS PharmSciTech; 2018 Jan; 19(1):470-480. PubMed ID: 28828580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on preparation of matrine double-sensitive colon-specific pellets and in vitro release].
    Zhang YG; Jie J
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1603-6. PubMed ID: 25095369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheo-dissolution: A new platform for the simultaneous measurement of rheology and drug release.
    Senjoti FG; Ghori MU; Diryak R; Conway BR; Morris GA; Smith AM
    Carbohydr Polym; 2020 Feb; 229():115541. PubMed ID: 31826516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of topical ophthalmic In Situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts.
    Kotreka UK; Davis VL; Adeyeye MC
    PLoS One; 2017; 12(2):e0172306. PubMed ID: 28222100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.